The UdG proves the effect of an Esteve drug that prevents spinal cord injury pain Blog Post

A team of scientists from the University of Girona (UdG) has shown the effect of an Esteve drug to prevent the development of the pathological pain resulting from a spinal cord injury. The study is of great importance because there are currently no medicines that are really effective against this pathological pain caused by spinal cord injury. With this research, the pharmaceutical group, which has its Drug Discovery and Preclinical Development Units at the Barcelona Science Park, is again committed to collaborative innovation to provide solutions to medical needs not covered in diseases of high social impact.

 

A nanodrone able to detect toxic gases in emergencies Blog Post

Detecting dangerous gases in collapsed buildings due earthquakes or explosions and identifying the presence of victims in places which are hard to access are some action scenarios of SNAV (Smelling Nano Aerial Vehicle), a nanodrone designed and created by the researchers Santiago Marco and Javier Burgués, from the Faculty of Physics of the University of Barcelona and the Institute for Bioengineering of Catalonia (IBEC), based in the Barcelona Science Park.

 

p38 protein regulates the formation of new blood vessels in tumours Blog Post

Researchers from the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park publish a study in the journal Nature Communications addressing the role of the p38 protein in angiogenesis—the formation of new blood vessels—a critical process that fuels tumour cells and allows them to grow and eventually develop metastases.

 

EIT Health Spain awards Headstart Programme support to Senolytic Therapeutics and Moirai Biodesign Blog Post

EIT Health Spain has announced today the 15 Spanish start-ups selected for 2019 Headstart Programe, which includes funding, mentoring and networking opportunities. Among those selected are Senolytic Therapeutics and Moirai Biodesign based in the Barcelona Science Park. Since 2016 the Spanish node of EIT Health, located in the Park, has supported more than 100 Spanish start-ups through a variety of acceleration programmes designed to support healthcare entrepreneurs at every stage of their business journey.

 

Núria Montserrat represents the European Research Council at the WEF Summer Davos in China Blog Post

Núria Montserrat, ICREA professor and principal investigator at the Institute for Bioengineering of Catalonia (IBEC) was among the nine scientists representatives of the European Research Council (ERC) at the Annual Meeting of the New Champions (AMNC), also known as “Summer Davos“. Organised by the World Economic Forum (WEF) in the Chinese city of Dailan from 1 to 3 July, the 2019 edition of this event brought together the brightest minds on the planet to discuss issues related to scientific research, leadership, and innovation. 

 

Unravelling the three-dimensional genomic structure of male germ cells Blog Post

A study led by scientists of the National Centre for Genomic Analysis (CNAG-CRG) –based in the Barcelona Science Park and integrated into the Centre for Genomic Regulation (CRG)–  and the Universitat Autònoma de Barcelona (UAB) reveals the three-dimensional genomic structure of male germ cells and how this structure determines their function. The study, published in the journal Cell Reports, represents a significant advance in our understanding of how the dynamics of insulator proteins and transcriptional activity are coupled during the 3D genome re-organisation that takes place during the formation of male germ cells.

 

Researchers at IRB Barcelona manage to selectively eliminate cells that express the RAS oncogene Blog Post

A team, led by ICREA researcher Marco Milán from the Institute for Research in Biomedicine (IRB Barcelona) at PCB, have managed to inhibit the capacity of RAS to block cell death, thus eliminating malignant tumours without affecting the development of organs.The results of the study pave the way to combining irradiation treatments with the administration of RAS pathway inhibitors to eliminate tumour cells.

 

GalChimia doubles the surface of its R&D&I center in the Barcelona Science Park Blog Post

Galician company GalChimia has doubled the facility and personnel count of its R&D&I center at the Barcelona Science Park, which was opened just a year ago to accelerate its growth and internationalization strategy an initiative to share the knowledge and experience of experts in the pharmaceutical and biotech industry in the field of discovery and drug development with its clients and the scientific community. Coinciding with the inauguration of its new laboratories, the company celebrated its first “GalChimia Day”, an initiative to share the knowledge and experience of experts in the pharmaceutical and biotech industry in the field of discovery and drug development with its clients and the scientific community.